Foxy-5

• Description:

  Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2][3].

• UNSPSC:

  12352209

• Target:

  Wnt

• Type:

  Peptides

• Related Pathways:

  Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/foxy-5.html

• Purity:

  99.56

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C([C@H](CS)NC(CNC([C@H](CC(O)=O)NC([C@@H](NC=O)CCSC)=O)=O)=O)N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC(C)C)=O

• Molecular Formula:

  C26H42N6O12S2

• Molecular Weight:

  694.77

• References & Citations:

  [1]Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14 (20) :6556-63.|[2]Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39 (4) :1719-1728.|[3]Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12 (9) :e0184418.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 2

• Isoform:

  Wnt5

• Citation 01:

  Int J Oral Sci. 2024 Feb 19;16 (1) :15.|iScience. 2024 Dec 1;27 (12) :111517.|Phytomedicine. 2025 Feb 10:139:156491.|J Neuroinflammation. 2024 Mar 26;21 (1) :75.|Patent. US20230130144A1.|Pathol Res Pract. 2024 May 26:259:155369.

• CAS Number:

  [881188-51-8]